Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
about
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsNew pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors.Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication.Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo TrialThe versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System.Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from Thai blood donors.The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
P2860
Q28481038-9CA71C0C-49C3-4144-BAD7-949003844A30Q34372464-229520F7-B298-48B3-BE89-C27F1F2C6FF0Q34571043-778C4556-D80D-4517-B4B2-69400089F752Q34587192-C13CC23A-87BB-4440-99CB-DBEFFBAE74CFQ36607811-A95ECE33-65DB-4F72-922B-E06E73376539Q37056536-30F965C1-48E3-4FDD-8958-C1A86DF74D36Q37638410-DA85873C-9DFA-4849-BB8F-9E7539941562Q38109095-22CD5070-F418-42FD-8436-5C35674C7D5AQ40042032-B1467EA4-1049-4821-9770-28CCD834F536Q40677384-BF5C32C0-BF65-4594-B5DD-B1774553B77CQ40831393-9FE1FB5B-209B-430A-9FBE-B42A40D3F49DQ42197246-8DE36CDF-6EEC-4B53-9B1F-D86D62B04E2DQ42249693-DB3E4F9F-8DB6-4FB2-9673-4257230DB9E4Q42988733-7A22E778-4F43-4497-A1A7-AAE5A5CCB7B3
P2860
Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Impact of HCV protease-inhibit ...... onic HCV genotype 1 infection.
@en
Impact of HCV protease-inhibit ...... onic HCV genotype 1 infection.
@nl
type
label
Impact of HCV protease-inhibit ...... onic HCV genotype 1 infection.
@en
Impact of HCV protease-inhibit ...... onic HCV genotype 1 infection.
@nl
prefLabel
Impact of HCV protease-inhibit ...... onic HCV genotype 1 infection.
@en
Impact of HCV protease-inhibit ...... onic HCV genotype 1 infection.
@nl
P356
P1433
P1476
Impact of HCV protease-inhibit ...... onic HCV genotype 1 infection.
@en
P2093
Peter Ferenci
P304
P356
10.3851/IMP1934
P577
2011-01-01T00:00:00Z